News

INOpulse is advancing in a number of clinical trials as a potential treatment of pulmonary hypertension (PH) associated with several lung diseases, Bellerophon Therapeutics reported in a recent announcement. The company is currently developing INOpulse to treat PH associated with chronic obstructive pulmonary disease (COPD), interstitial lung…

The severity of pulmonary hypertension (PH) increases the risk of fetus death, although mortality among PH pregnant women is low, according to a Chinese review study. The study, “Pregnancy and pulmonary hypertension: An exploratory analysis of risk factors and outcomes” was published in the journal Medicine. Pregnancy induces…

Treprostinil is a therapy that works to reduce pulmonary artery narrowing in people with pulmonary arterial hypertension (PAH) by preventing artery wall remodeling processes. That finding comes from a research study investigating the medicine’s molecular effects using patient lung artery cells suggests. Treprostinil appears to…

Transgelin, a smooth muscle protein, is abundant in patients with irreversible pulmonary arterial hypertension (PAH) secondary to congenital heart disease and may contribute to PAH progression, a study reports. The study, “Transgelin as a potential target in the reversibility of pulmonary arterial hypertension secondary to congenital heart disease,” was…

Patients with mild pulmonary hypertension (PH), with a mean pulmonary arterial pressure between 19 and 21 mmHg, are at significant risk of death, indicating a need for adjustment of the mPAP diagnostic value. The study, “Mild Pulmonary Hypertension Is Associated with Increased Mortality: A Systematic Review and Meta-Analysis,”…

The Pulmonary Hypertension Association (PHA) will be using social media throughout this month to increase awareness about issues affecting patients with pulmonary hypertension (PH) within the medical community, the general public, and members of Congress. PHA is also organizing fundraising events to support PH research and education as part of their outreach…

Liquidia Technologies has completed the enrollment for the safety part of a Phase 3 trial evaluating the safety and tolerability of LIQ861, an inhaled dry power formulation of treprostinil for the treatment of pulmonary arterial hypertension…

Patients with pulmonary hypertension (PH) and severe aortic stenosis (AS), who have a specific, less frequent blood flow pattern, have worse cardiac function and increased mortality, according to a study. The study, “Haemodynamic mechanisms and long‐term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve…

Treatment with inhaled Ventavis (iloprost) has limited effectiveness in improving the survival rate of patients with pulmonary arterial hypertension (PAH), despite the clinical improvements it induces, real-world data suggests. These findings resulted from an analysis of data collected in the observational Spanish REHAP registry. They were recently reported in…

With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Creditand affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate, or…

A set of new genes and signaling pathways linked to the development of severe lung disease in premature infants was found by researchers from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago and collaborators. Their study, “Exome sequencing identifies gene variants and…

Portopulmonary hypertension (PoPH) affects a significant proportion of patients who undergo a liver transplant and significantly worsens their outcomes if left untreated, a Chinese study reports. The research underlines the importance of screening liver transplant recipients for PoPH, and treating those with the condition…